There are 3484 resources available
Invited Discussant 723O and LBA53
Presenter: Marianne Pavel
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Webcast
False dichotomies and going beyond screening
Presenter: Mary Gospodarowicz
Session: Current issues in primary prevention and screening to block the onset or development of cancer
Resources:
Slides
Webcast
Best Publication from a Fellowship
Presenter: Michael-John Devlin
Session: YO Fellowship Session: Fellowships in Europe: Educational opportunities for young oncologists
Resources:
Slides
Webcast
LBA89 - Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas
Presenter: Robin Jones
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA101 - BRCA-DIRECT: A randomised UK study evaluating a digital pathway for germline genetic testing and non-inferiority of digitally-delivered information in women with breast cancer
Presenter: Bethany Torr
Session: Mini oral session - Basic science & translational research
Resources:
Abstract
Slides
Webcast
382MO - Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
Presenter: Nancy Lin
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
ctDNA in early-stage CRC: Tailoring the adjuvant therapy
Presenter: Julien Taieb
Session: Circulating tumour DNA: A perfect fit?
Resources:
Slides
Webcast
Invited Discussant 1766MO, 1767MO and 1768MO
Presenter: Boris Hadaschik
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
Novel combinations in the non-curative HNSCC setting
Presenter: Brigette Ma
Session: Immunotherapy for head and neck cancer: What, when and how long?
Resources:
Slides
Webcast